NFA
TARA icon

Nationwide Fund Advisors’s Protara Therapeutics TARA Stock Holding History

Nationwide Fund Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-120
Closed -$37K – 3297
2016
Q1 		$37K Hold
120
– – ﹤0.01% 3035
2015
Q4 		$75K Hold
120
– – ﹤0.01% 2918
2015
Q3 		$67K Hold
120
– – ﹤0.01% 2986
2015
Q2 		$86K Buy
+120
New +$74.2K ﹤0.01% 3041

Other funds holding TARA

TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Nationwide Fund Advisors's TARA Position: Q2 2016 in Review

Nationwide Fund Advisors sold out of Protara Therapeutics (TARA) in Q2 2016, closing a stake of 120 shares — an estimated $37K sold.

Nationwide Fund Advisors first reported a position in TARA in Q2 2015 and held it in 4 quarters. The position peaked at $86K in Q2 2015. 32 funds tracked by Wall St. Rank hold TARA as of Q2 2016.

  • Nationwide Fund Advisors reported no remaining Protara Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Nationwide Fund Advisors sold 120 Protara Therapeutics shares in Q2 2016, an estimated $37K.
  • Nationwide Fund Advisors first reported a position in Protara Therapeutics in Q2 2015 and held it in 4 quarters.
  • Nationwide Fund Advisors's Protara Therapeutics position peaked at $86K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2016.

Based on Nationwide Fund Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.